Trinity Biotech (TRIB) Net Cash Flow (2017 - 2024)

Trinity Biotech (TRIB) has reported Net Cash Flow for 6 consecutive years, with $2.7 million the latest figure, recorded in Q4 2024.

• Quarterly Net Cash Flow rose 213.0% year-over-year to $2.7 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $2.7 million (up 309.31% YoY) and the FY2025 annual result came in at -$100000.0, down 115.6% from the prior year.
• Net Cash Flow improved to $2.7 million in Q4 2024 per TRIB's latest filing, from -$3.9 million in the prior quarter.
• Over the last five years, Net Cash Flow for TRIB reached as high as $2.7 million in Q4 2024 and fell as low as -$7.1 million in Q2 2023.
• A 4-year average of -$1.7 million and a median of -$1.4 million in 2021 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 282312.79% — and 2024, when it surged 213.0%.
• Year by year, Net Cash Flow stood at -$2.2 million in 2021, then surged by 67.66% to -$696000.0 in 2022, then plunged by 237.21% to -$2.3 million in 2023, then jumped by 213.0% to $2.7 million in 2024.
• According to Business Quant data, Net Cash Flow over the past three periods registered $2.7 million, -$3.9 million, and -$3317.0 for Q4 2024, Q2 2024, and Q1 2024 respectively.